APO Research
Talk to an analyst

APO RESEARCH · REPORT

Gemcitabine Injection

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Gemcitabine Injection Market Outlook and Growth Opportunities 2026

2 January 2026196 pages

Choose your research edition.

Industry ResearchGemcitabine Injection Industry Research Report 2026118 pages · $2,950 USDIndustry Growth & TrendsGlobal Gemcitabine Injection Industry Growth and Trends Forecast to 203293 pages · $3,450 USDMarket StructureGlobal Gemcitabine Injection Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032185 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Gemcitabine Injection Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Gemcitabine Injection Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Gemcitabine Injection market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Gemcitabine Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Gemcitabine Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Gemcitabine Injection is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Gemcitabine Injection market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Gemcitabine Injection market include Teva Pharmaceuticals, Novartis AG, Mylan Inc, Pfizer, Fresenius Kabi, Meitheal Pharmaceuticals and Accord Healthcare, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Gemcitabine Injection market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Gemcitabine Injection and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Gemcitabine Injection sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Gemcitabine Injection market size, projected growth trends, production technologies, key applications, and end-use industries.

Gemcitabine Injection Segment by Company

Teva Pharmaceuticals

Novartis AG

Mylan Inc

Pfizer

Fresenius Kabi

Meitheal Pharmaceuticals

Accord Healthcare

Gemcitabine Injection Segment by Type

1g/26.3 mL

200mg/5.26 mL

2g/52.6 mL

Gemcitabine Injection Segment by Application

Hospital

Clinic

Gemcitabine Injection Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Gemcitabine Injection status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Gemcitabine Injection market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Gemcitabine Injection significant trends, drivers, influence factors in global and regions.

6. To analyze Gemcitabine Injection competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Gemcitabine Injection market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Gemcitabine Injection and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Gemcitabine Injection.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Gemcitabine Injection market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Gemcitabine Injection industry.

Chapter 3: Detailed analysis of Gemcitabine Injection manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Gemcitabine Injection in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Gemcitabine Injection in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Gemcitabine Injection Industry Trends Table 2. Gemcitabine Injection Industry Drivers Table 3. Gemcitabine Injection Industry Opportunities and Challenges Table 4. Gemcitabine Injection Industry Restraints Table 5. Global Gemcitabine Injection Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Gemcitabine Injection Revenue Share by Company (2021-2026) Table 7. Global Gemcitabine Injection Sales Volume by Company (K L) & (2021-2026) Table 8. Global Gemcitabine Injection Sales Volume Share by Company (2021-2026) Table 9. Global Gemcitabine Injection Average Price (US$/L) of Company (2021-2026) Table 10. Global Gemcitabine Injection Company Ranking, (2024-2026) & (USD Million) Table 11. Global Gemcitabine Injection Key Company Manufacturing Base & Headquarters Table 12. Global Gemcitabine Injection Company, Product Type & Application Table 13. Global Gemcitabine Injection Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Gemcitabine Injection by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of 1g/26.3 mL Table 18. Significant Companies of 200mg/5.26 mL Table 19. Significant Companies of 2g/52.6 mL Table 20. Global Gemcitabine Injection Sales Volume by Type 2021 VS 2025 VS 2032 (K L) Table 21. Global Gemcitabine Injection Sales Volume by Type (2021-2026) & (K L) Table 22. Global Gemcitabine Injection Sales Volume by Type (2027-2032) & (K L) Table 23. Global Gemcitabine Injection Sales Volume Share by Type (2021-2026) Table 24. Global Gemcitabine Injection Sales Volume Share by Type (2027-2032) Table 25. Global Gemcitabine Injection Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Gemcitabine Injection Sales Value by Type (2021-2026) & (US$ Million) Table 27. Global Gemcitabine Injection Sales Value by Type (2027-2032) & (US$ Million) Table 28. Global Gemcitabine Injection Sales Value Share by Type (2021-2026) Table 29. Global Gemcitabine Injection Sales Value Share by Type (2027-2032) Table 30. Significant Companies of Hospital Table 31. Significant Companies of Clinic Table 32. Global Gemcitabine Injection Sales Volume by Application 2021 VS 2025 VS 2032 (K L) Table 33. Global Gemcitabine Injection Sales Volume by Application (2021-2026) & (K L) Table 34. Global Gemcitabine Injection Sales Volume by Application (2027-2032) & (K L) Table 35. Global Gemcitabine Injection Sales Volume Share by Application (2021-2026) Table 36. Global Gemcitabine Injection Sales Volume Share by Application (2027-2032) Table 37. Global Gemcitabine Injection Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Gemcitabine Injection Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global Gemcitabine Injection Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global Gemcitabine Injection Sales Value Share by Application (2021-2026) Table 41. Global Gemcitabine Injection Sales Value Share by Application (2027-2032) Table 42. Global Gemcitabine Injection Sales by Region: 2021 VS 2025 VS 2032 (K L) Table 43. Global Gemcitabine Injection Sales by Region (2021-2026) & (K L) Table 44. Global Gemcitabine Injection Sales Market Share by Region (2021-2026) Table 45. Global Gemcitabine Injection Sales by Region (2027-2032) & (K L) Table 46. Global Gemcitabine Injection Sales Market Share by Region (2027-2032) Table 47. Global Gemcitabine Injection Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Gemcitabine Injection Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global Gemcitabine Injection Sales Value Share by Region (2021-2026) Table 50. Global Gemcitabine Injection Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global Gemcitabine Injection Sales Value Share by Region (2027-2032) Table 52. Global Gemcitabine Injection Market Average Price (US$/L) by Region (2021-2026) Table 53. Global Gemcitabine Injection Market Average Price (US$/L) by Region (2027-2032) Table 54. Global Gemcitabine Injection Sales by Country: 2021 VS 2025 VS 2032 (K L) Table 55. Global Gemcitabine Injection Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global Gemcitabine Injection Sales by Country (2021-2026) & (K L) Table 57. Global Gemcitabine Injection Sales Market Share by Country (2021-2026) Table 58. Global Gemcitabine Injection Sales by Country (2027-2032) & (K L) Table 59. Global Gemcitabine Injection Sales Market Share by Country (2027-2032) Table 60. Global Gemcitabine Injection Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global Gemcitabine Injection Sales Value Market Share by Country (2021-2026) Table 62. Global Gemcitabine Injection Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global Gemcitabine Injection Sales Value Market Share by Country (2027-2032) Table 64. Teva Pharmaceuticals Company Information Table 65. Teva Pharmaceuticals Business Overview Table 66. Teva Pharmaceuticals Gemcitabine Injection Sales (K L), Value (US$ Million), Price (US$/L) and Gross Margin (2021-2026) Table 67. Teva Pharmaceuticals Gemcitabine Injection Product Portfolio Table 68. Teva Pharmaceuticals Recent Development Table 69. Novartis AG Company Information Table 70. Novartis AG Business Overview Table 71. Novartis AG Gemcitabine Injection Sales (K L), Value (US$ Million), Price (US$/L) and Gross Margin (2021-2026) Table 72. Novartis AG Gemcitabine Injection Product Portfolio Table 73. Novartis AG Recent Development Table 74. Mylan Inc Company Information Table 75. Mylan Inc Business Overview Table 76. Mylan Inc Gemcitabine Injection Sales (K L), Value (US$ Million), Price (US$/L) and Gross Margin (2021-2026) Table 77. Mylan Inc Gemcitabine Injection Product Portfolio Table 78. Mylan Inc Recent Development Table 79. Pfizer Company Information Table 80. Pfizer Business Overview Table 81. Pfizer Gemcitabine Injection Sales (K L), Value (US$ Million), Price (US$/L) and Gross Margin (2021-2026) Table 82. Pfizer Gemcitabine Injection Product Portfolio Table 83. Pfizer Recent Development Table 84. Fresenius Kabi Company Information Table 85. Fresenius Kabi Business Overview Table 86. Fresenius Kabi Gemcitabine Injection Sales (K L), Value (US$ Million), Price (US$/L) and Gross Margin (2021-2026) Table 87. Fresenius Kabi Gemcitabine Injection Product Portfolio Table 88. Fresenius Kabi Recent Development Table 89. Meitheal Pharmaceuticals Company Information Table 90. Meitheal Pharmaceuticals Business Overview Table 91. Meitheal Pharmaceuticals Gemcitabine Injection Sales (K L), Value (US$ Million), Price (US$/L) and Gross Margin (2021-2026) Table 92. Meitheal Pharmaceuticals Gemcitabine Injection Product Portfolio Table 93. Meitheal Pharmaceuticals Recent Development Table 94. Accord Healthcare Company Information Table 95. Accord Healthcare Business Overview Table 96. Accord Healthcare Gemcitabine Injection Sales (K L), Value (US$ Million), Price (US$/L) and Gross Margin (2021-2026) Table 97. Accord Healthcare Gemcitabine Injection Product Portfolio Table 98. Accord Healthcare Recent Development Table 99. Key Raw Materials Table 100. Raw Materials Key Suppliers Table 101. Gemcitabine Injection Distributors List Table 102. Gemcitabine Injection Customers List Table 103. Research Programs/Design for This Report Table 104. Authors List of This Report Table 105. Secondary Sources Table 106. Primary Sources List of Figures Figure 1. Gemcitabine Injection Product Image Figure 2. Global Gemcitabine Injection Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Gemcitabine Injection Sales Value (2021-2032) & (US$ Million) Figure 4. Global Gemcitabine Injection Sales (2021-2032) & (K L) Figure 5. Global Gemcitabine Injection Sales Average Price (US$/L) & (2021-2032) Figure 6. Global Gemcitabine Injection Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. 1g/26.3 mL Image Figure 10. 200mg/5.26 mL Image Figure 11. 2g/52.6 mL Image Figure 12. Global Gemcitabine Injection Sales Volume by Type (2021 VS 2025 VS 2032) & (K L) Figure 13. Global Gemcitabine Injection Sales Volume Share 2021 VS 2025 VS 2032 Figure 14. Global Gemcitabine Injection Sales Volume Share by Type (2021-2032) Figure 15. Global Gemcitabine Injection Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Gemcitabine Injection Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Gemcitabine Injection Sales Value Share by Type (2021-2032) Figure 18. Hospital Image Figure 19. Clinic Image Figure 20. Global Gemcitabine Injection Sales Volume by Application (2021 VS 2025 VS 2032) & (K L) Figure 21. Global Gemcitabine Injection Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global Gemcitabine Injection Sales Volume Share by Application (2021-2032) Figure 23. Global Gemcitabine Injection Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Gemcitabine Injection Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global Gemcitabine Injection Sales Value Share by Application (2021-2032) Figure 26. Global Gemcitabine Injection Sales by Region: 2021 VS 2025 VS 2032 (K L) Figure 27. Global Gemcitabine Injection Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global Gemcitabine Injection Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global Gemcitabine Injection Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America Gemcitabine Injection Sales Value (2021-2032) & (US$ Million) Figure 31. North America Gemcitabine Injection Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe Gemcitabine Injection Sales Value (2021-2032) & (US$ Million) Figure 33. Europe Gemcitabine Injection Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific Gemcitabine Injection Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific Gemcitabine Injection Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America Gemcitabine Injection Sales Value (2021-2032) & (US$ Million) Figure 37. South America Gemcitabine Injection Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa Gemcitabine Injection Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa Gemcitabine Injection Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA Gemcitabine Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA Gemcitabine Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA Gemcitabine Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada Gemcitabine Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada Gemcitabine Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada Gemcitabine Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico Gemcitabine Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico Gemcitabine Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico Gemcitabine Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany Gemcitabine Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany Gemcitabine Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany Gemcitabine Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France Gemcitabine Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France Gemcitabine Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France Gemcitabine Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. Gemcitabine Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. Gemcitabine Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. Gemcitabine Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy Gemcitabine Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy Gemcitabine Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy Gemcitabine Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain Gemcitabine Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain Gemcitabine Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain Gemcitabine Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia Gemcitabine Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia Gemcitabine Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia Gemcitabine Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands Gemcitabine Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands Gemcitabine Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands Gemcitabine Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries Gemcitabine Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries Gemcitabine Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries Gemcitabine Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China Gemcitabine Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China Gemcitabine Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China Gemcitabine Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan Gemcitabine Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan Gemcitabine Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan Gemcitabine Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea Gemcitabine Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea Gemcitabine Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea Gemcitabine Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India Gemcitabine Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India Gemcitabine Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India Gemcitabine Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia Gemcitabine Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia Gemcitabine Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia Gemcitabine Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia Gemcitabine Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia Gemcitabine Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia Gemcitabine Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil Gemcitabine Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil Gemcitabine Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil Gemcitabine Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina Gemcitabine Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina Gemcitabine Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina Gemcitabine Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile Gemcitabine Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile Gemcitabine Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile Gemcitabine Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia Gemcitabine Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia Gemcitabine Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia Gemcitabine Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru Gemcitabine Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru Gemcitabine Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru Gemcitabine Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia Gemcitabine Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia Gemcitabine Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Gemcitabine Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel Gemcitabine Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia Gemcitabine Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia Gemcitabine Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE Gemcitabine Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE Gemcitabine Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE Gemcitabine Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey Gemcitabine Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey Gemcitabine Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey Gemcitabine Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran Gemcitabine Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran Gemcitabine Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran Gemcitabine Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt Gemcitabine Injection Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt Gemcitabine Injection Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt Gemcitabine Injection Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Gemcitabine Injection Value Chain Figure 125. Manufacturing Cost Structure Figure 126. Gemcitabine Injection Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • 1g/26.3 mL
  • 200mg/5.26 mL
  • 2g/52.6 mL
Applications
  • Hospital
  • Clinic
Companies covered
  • Teva Pharmaceuticals
  • Novartis AG
  • Mylan Inc
  • Pfizer
  • Fresenius Kabi
  • Meitheal Pharmaceuticals
  • Accord Healthcare

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Gemcitabine Injection Sales Value (2021-2032)
  4. 1.2.2 Global Gemcitabine Injection Sales Volume (2021-2032)
  5. 1.2.3 Global Gemcitabine Injection Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Gemcitabine Injection Market Dynamics
  1. 2.1 Gemcitabine Injection Industry Trends
  2. 2.2 Gemcitabine Injection Industry Drivers
  3. 2.3 Gemcitabine Injection Industry Opportunities and Challenges
  4. 2.4 Gemcitabine Injection Industry Restraints
3 Gemcitabine Injection Market by Company
  1. 3.1 Global Gemcitabine Injection Company Revenue Ranking in 2025
  2. 3.2 Global Gemcitabine Injection Revenue by Company (2021-2026)
  3. 3.3 Global Gemcitabine Injection Sales Volume by Company (2021-2026)
  4. 3.4 Global Gemcitabine Injection Average Price by Company (2021-2026)
  5. 3.5 Global Gemcitabine Injection Company Ranking (2024-2026)
  6. 3.6 Global Gemcitabine Injection Company Manufacturing Base and Headquarters
  7. 3.7 Global Gemcitabine Injection Company Product Type and Application
  8. 3.8 Global Gemcitabine Injection Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Gemcitabine Injection Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Gemcitabine Injection Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Gemcitabine Injection Market by Type
  1. 4.1 Gemcitabine Injection Type Introduction
  2. 4.1.1 1g/26.3 mL
  3. 4.1.2 200mg/5.26 mL
  4. 4.1.3 2g/52.6 mL
  5. 4.2 Global Gemcitabine Injection Sales Volume by Type
  6. 4.2.1 Global Gemcitabine Injection Sales Volume by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Gemcitabine Injection Sales Volume by Type (2021-2032)
  8. 4.2.3 Global Gemcitabine Injection Sales Volume Share by Type (2021-2032)
  9. 4.3 Global Gemcitabine Injection Sales Value by Type
  10. 4.3.1 Global Gemcitabine Injection Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Gemcitabine Injection Sales Value by Type (2021-2032)
  12. 4.3.3 Global Gemcitabine Injection Sales Value Share by Type (2021-2032)
5 Gemcitabine Injection Market by Application
  1. 5.1 Gemcitabine Injection Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.2 Global Gemcitabine Injection Sales Volume by Application
  5. 5.2.1 Global Gemcitabine Injection Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Gemcitabine Injection Sales Volume by Application (2021-2032)
  7. 5.2.3 Global Gemcitabine Injection Sales Volume Share by Application (2021-2032)
  8. 5.3 Global Gemcitabine Injection Sales Value by Application
  9. 5.3.1 Global Gemcitabine Injection Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Gemcitabine Injection Sales Value by Application (2021-2032)
  11. 5.3.3 Global Gemcitabine Injection Sales Value Share by Application (2021-2032)
6 Gemcitabine Injection Regional Sales and Value Analysis
  1. 6.1 Global Gemcitabine Injection Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Gemcitabine Injection Sales by Region (2021-2032)
  3. 6.2.1 Global Gemcitabine Injection Sales by Region: 2021-2026
  4. 6.2.2 Global Gemcitabine Injection Sales by Region (2027-2032)
  5. 6.3 Global Gemcitabine Injection Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Gemcitabine Injection Sales Value by Region (2021-2032)
  7. 6.4.1 Global Gemcitabine Injection Sales Value by Region: 2021-2026
  8. 6.4.2 Global Gemcitabine Injection Sales Value by Region (2027-2032)
  9. 6.5 Global Gemcitabine Injection Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Gemcitabine Injection Sales Value (2021-2032)
  12. 6.6.2 North America Gemcitabine Injection Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Gemcitabine Injection Sales Value (2021-2032)
  15. 6.7.2 Europe Gemcitabine Injection Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Gemcitabine Injection Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Gemcitabine Injection Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Gemcitabine Injection Sales Value (2021-2032)
  21. 6.9.2 South America Gemcitabine Injection Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Gemcitabine Injection Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Gemcitabine Injection Sales Value Share by Country, 2025 VS 2032
7 Gemcitabine Injection Country-level Sales and Value Analysis
  1. 7.1 Global Gemcitabine Injection Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Gemcitabine Injection Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Gemcitabine Injection Sales by Country (2021-2032)
  4. 7.3.1 Global Gemcitabine Injection Sales by Country (2021-2026)
  5. 7.3.2 Global Gemcitabine Injection Sales by Country (2027-2032)
  6. 7.4 Global Gemcitabine Injection Sales Value by Country (2021-2032)
  7. 7.4.1 Global Gemcitabine Injection Sales Value by Country (2021-2026)
  8. 7.4.2 Global Gemcitabine Injection Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Gemcitabine Injection Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Gemcitabine Injection Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Gemcitabine Injection Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Gemcitabine Injection Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Gemcitabine Injection Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Gemcitabine Injection Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Gemcitabine Injection Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Gemcitabine Injection Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Gemcitabine Injection Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Gemcitabine Injection Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Gemcitabine Injection Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Gemcitabine Injection Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Gemcitabine Injection Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Gemcitabine Injection Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Gemcitabine Injection Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Gemcitabine Injection Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Gemcitabine Injection Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Gemcitabine Injection Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Gemcitabine Injection Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Gemcitabine Injection Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Gemcitabine Injection Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Gemcitabine Injection Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Gemcitabine Injection Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Gemcitabine Injection Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Gemcitabine Injection Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Gemcitabine Injection Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Gemcitabine Injection Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Gemcitabine Injection Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Gemcitabine Injection Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Gemcitabine Injection Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Gemcitabine Injection Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Gemcitabine Injection Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Gemcitabine Injection Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Gemcitabine Injection Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Gemcitabine Injection Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Gemcitabine Injection Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Gemcitabine Injection Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Gemcitabine Injection Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Gemcitabine Injection Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Gemcitabine Injection Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Gemcitabine Injection Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Gemcitabine Injection Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Gemcitabine Injection Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Gemcitabine Injection Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Gemcitabine Injection Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Gemcitabine Injection Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Gemcitabine Injection Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Gemcitabine Injection Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Gemcitabine Injection Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Gemcitabine Injection Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Gemcitabine Injection Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Gemcitabine Injection Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Gemcitabine Injection Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Gemcitabine Injection Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Gemcitabine Injection Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Gemcitabine Injection Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Gemcitabine Injection Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Gemcitabine Injection Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Gemcitabine Injection Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Gemcitabine Injection Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Gemcitabine Injection Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Gemcitabine Injection Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Gemcitabine Injection Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Gemcitabine Injection Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Gemcitabine Injection Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Gemcitabine Injection Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Gemcitabine Injection Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Gemcitabine Injection Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Gemcitabine Injection Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Gemcitabine Injection Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Gemcitabine Injection Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Gemcitabine Injection Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Gemcitabine Injection Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Gemcitabine Injection Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Gemcitabine Injection Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Gemcitabine Injection Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Gemcitabine Injection Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Gemcitabine Injection Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Gemcitabine Injection Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Gemcitabine Injection Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Gemcitabine Injection Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Gemcitabine Injection Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Gemcitabine Injection Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Gemcitabine Injection Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Teva Pharmaceuticals
  2. 8.1.1 Teva Pharmaceuticals Company Information
  3. 8.1.2 Teva Pharmaceuticals Business Overview
  4. 8.1.3 Teva Pharmaceuticals Gemcitabine Injection Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Teva Pharmaceuticals Gemcitabine Injection Product Portfolio
  6. 8.1.5 Teva Pharmaceuticals Recent Developments
  7. 8.2 Novartis AG
  8. 8.2.1 Novartis AG Company Information
  9. 8.2.2 Novartis AG Business Overview
  10. 8.2.3 Novartis AG Gemcitabine Injection Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Novartis AG Gemcitabine Injection Product Portfolio
  12. 8.2.5 Novartis AG Recent Developments
  13. 8.3 Mylan Inc
  14. 8.3.1 Mylan Inc Company Information
  15. 8.3.2 Mylan Inc Business Overview
  16. 8.3.3 Mylan Inc Gemcitabine Injection Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Mylan Inc Gemcitabine Injection Product Portfolio
  18. 8.3.5 Mylan Inc Recent Developments
  19. 8.4 Pfizer
  20. 8.4.1 Pfizer Company Information
  21. 8.4.2 Pfizer Business Overview
  22. 8.4.3 Pfizer Gemcitabine Injection Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Pfizer Gemcitabine Injection Product Portfolio
  24. 8.4.5 Pfizer Recent Developments
  25. 8.5 Fresenius Kabi
  26. 8.5.1 Fresenius Kabi Company Information
  27. 8.5.2 Fresenius Kabi Business Overview
  28. 8.5.3 Fresenius Kabi Gemcitabine Injection Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Fresenius Kabi Gemcitabine Injection Product Portfolio
  30. 8.5.5 Fresenius Kabi Recent Developments
  31. 8.6 Meitheal Pharmaceuticals
  32. 8.6.1 Meitheal Pharmaceuticals Company Information
  33. 8.6.2 Meitheal Pharmaceuticals Business Overview
  34. 8.6.3 Meitheal Pharmaceuticals Gemcitabine Injection Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Meitheal Pharmaceuticals Gemcitabine Injection Product Portfolio
  36. 8.6.5 Meitheal Pharmaceuticals Recent Developments
  37. 8.7 Accord Healthcare
  38. 8.7.1 Accord Healthcare Company Information
  39. 8.7.2 Accord Healthcare Business Overview
  40. 8.7.3 Accord Healthcare Gemcitabine Injection Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Accord Healthcare Gemcitabine Injection Product Portfolio
  42. 8.7.5 Accord Healthcare Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Gemcitabine Injection Value Chain Analysis
  2. 9.1.1 Gemcitabine Injection Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Gemcitabine Injection Sales Mode & Process
  6. 9.2 Gemcitabine Injection Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Gemcitabine Injection Distributors
  9. 9.2.3 Gemcitabine Injection Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst